^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rasdegafusp alfa (CDX-1401)

    i
    Associations
    News

    Trials

    Company:
    Celldex
    Drug class:
    Immunostimulant, NY ESO 1 inhibitor, Dendritic cell activator, DEC-205 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03206047)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    11/08/2017
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    PD-L1 • CTAG1B
    |
    PD-L1 expression • CTAG1B expression
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)
    DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT02166905)
    Phase 1/2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    02/24/2023
    Initiation :
    10/10/2014
    Primary completion :
    08/20/2020
    Completion :
    08/20/2020
    CTAG1B • CD4 • CTAG2
    |
    epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)
    A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/16/2021
    Initiation :
    04/09/2014
    Primary completion :
    03/28/2016
    Completion :
    05/18/2018
    CTAG1B • CD4 • PRAME
    |
    CTAG1B expression
    |
    Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)
    DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT03358719)
    Phase 1
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    10/05/2021
    Initiation :
    03/27/2018
    Primary completion :
    02/27/2020
    Completion :
    08/25/2021
    CTAG1B
    |
    Opdivo (nivolumab) • azacitidine • decitabine • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)
    Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer (NCT02495636)
    Phase 2
    Yale University
    Withdrawn
    Last update posted :
    06/22/2017
    Initiation :
    07/01/2015
    Primary completion :
    07/01/2017
    Completion :
    07/01/2017
    ALK • CTAG1B
    |
    EGFR mutation • ALK rearrangement • CTAG1B expression • EGFR rearrangement
    |
    Tecentriq (atezolizumab) • rasdegafusp alfa (CDX-1401)
    A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients (NCT02661100)
    Phase 1/2
    Case Comprehensive Cancer Center
    Withdrawn
    Last update posted :
    12/07/2016
    Initiation :
    01/01/2017
    Primary completion :
    07/01/2018
    Completion :
    07/01/2018
    CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)
    Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820)
    Phase 1
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    10/04/2016
    Initiation :
    03/01/2012
    Primary completion :
    07/01/2016
    Completion :
    07/01/2016
    ER • CTAG1B • CTAG2
    |
    ER positive • ER negative
    |
    cisplatin • sirolimus • rasdegafusp alfa (CDX-1401)
    A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 (NCT00948961)
    Phase 1/2
    Celldex Therapeutics
    Completed
    Last update posted :
    06/27/2016
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2012
    Completion :
    02/01/2014
    CTAG1B
    |
    CTAG1B expression
    |
    Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)